Tirzepatide is a 39-amino acid synthetic peptide that acts as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It was designed based on the native GIP sequence with modifications that confer GLP-1 receptor binding activity.
Structural Design
The peptide is acylated with a C20 fatty diacid moiety via a linker attached to Lys20. This modification enables albumin binding, extending the half-life to approximately 5 days. The key amino acid substitutions (particularly at positions 1, 13, 14, 17, 20, and 30) determine the balance of GIP and GLP-1 receptor affinity.
Incretin Biology
GIP and GLP-1 are both incretin hormones released from the gut in response to nutrient ingestion. By activating both receptors, tirzepatide engages complementary metabolic pathways โ GLP-1R-mediated appetite reduction and GIP-R-mediated effects on fat metabolism and energy expenditure.